ClinicalTrials.gg
Active, not recruitingNCT06594705JENA-VADUpdated Oct 29, 2026

The JenaValve ALIGN-AR LVAD Registry

An interventional study of JenaValve Trilogy Heart Valve System in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by JenaValve Technology, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Primary completion movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.

Enrollment
20th of 24
50 · median 226
Started
2024
with 2 others
No phase
22 of 41
3 open now
Primary completion
2026-08
later than 6 of 16 live
Registered
37th of 41
by date
Lead sponsor
4 of 41
JenaValve Technology, Inc.

Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 22 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 37th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Aortic Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR) who are indicated for TAVR

03

Conditions studied

  • Aortic Regurgitation
  • Aortic Valve Insufficiency
  • Aortic Insufficiency
  • Aortic Valve Disease
  • Left Ventricular Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects \>=18 years of age with continuous flow LVAD (cfLVAD) with AR1 leading to cfLVAD dysfunction using cfLVAD ASE guidelines that utilize contemporary management strategies for measurement of AR in patients with cfLVAD2,3:

    • AR is graded from 0 to 6 (0 = none; 1 = trace; 2 = mild; 3 = mild-to-moderate; 4 = moderate; 5 = moderate-to-severe; 6 = severe). Considering that AR during continuous flow LVAD (cfLVAD) support is generally both systolic and diastolic, AR is deemed significant if graded ≥ 3.1
  2. Patient with functional class III/IV
  3. Patient with high risk for SAVR as documented by Heart Team.
  4. Patient has suitable anatomy to accommodate the insertion and delivery of the JenaValve Trilogy™ Heart Valve System
  5. Patient or the patient's legal representative has provided written
  6. Patient or the patient's legal representative agrees to comply with all required post-procedure follow-up visits

Exclusion criteria

Exclusion Criteria:

  1. Congenital uni- or bicuspid (Sievers 0) aortic valve morphology
  2. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  3. Mitral regurgitation \> moderate
  4. coronary artery disease (CAD) requiring revascularization within 30 days prior to index procedure, or planned CAD revascularization procedure within 12 months after index procedure
  5. Echocardiographic or CT evidence of left ventricular or aortic valve thrombus
  6. Ongoing sepsis or active infective endocarditis with ongoing antibiotic (including suppressive) therapy or positive blood cultures within 6 weeks
  7. Hypertrophic cardiomyopathy with or without obstruction
  8. Severe pulmonary hypertension (systolic PA pressure \>80 mmHg)
  9. Decompensated right heart failure as assessed clinically and, if available, by baseline right heart catheterization hemodynamics (e.g., right atrial pressure > pulmonary capillary wedge pressure and cardiac index \< 2.5 L/min/m2
  10. Severe RV dysfunction as assessed clinically and by echocardiography
  11. Aortic annular diameter of \<21.0 mm or > 28.6 mm (assessed by Multi-detector CT measurement)
  12. Aortic annulus angulation > 70° (assessed by Multi-detector CT measurement)
  13. Straight length of ascending aorta of \< 55 mm
  14. Significant disease of ascending aorta, including ascending aortic aneurysm (defined as maximal luminal diameter of 50 mm or greater) or atheroma (including if thick [>5 mm], protruding or ulcerated)
  15. Myocardial infarction \< 30 days prior to index procedure
  16. Cerebrovascular event (, stroke) \< 180 days prior to index procedure
  17. Blood dyscrasias as defined: leukopenia (WBC \< 3000/mm³), or thrombocytopenia ( \< 90,000/μl) or anemia (Men: \< 8.1 g/dl; Women: Hgb \< 7.4 g/dl)
  18. Active peptic ulcer or upper gastrointestinal bleeding \< 90 days prior to index procedure
  19. Known or to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be premedicated
  20. Subject unable to undergo pre-procedure transesophageal echocardiography or Multi-Detector CT (MDCT) scan for aortic annular sizing
  21. Patient is enrolled in another medical device or drug study which has not completed the required primary endpoint follow-up. (Note: Patients involved in a long-term surveillance phase of another study are eligible for enrollment in this registry)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    TAVR in LVAD Patients

    Transcatheter Aortic Valve Replacement (TAVR) TAVR in patients with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR)

    Device: JenaValve Trilogy Heart Valve System

Interventions

  • DeviceJenaValve Trilogy Heart Valve System

    TAVR with JenaValve Trilogy Heart Valve System

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint: Modified VARC-3 Device Success

    Device Success at 30 Days according to Valve Academic Research Consortium (VARC)-3 definition and modified for the LVAD population consisting of: - Freedom from all-cause mortality - Freedom from unsuccessful delivery of the device, and retrieval of the delivery system - Freedom from incorrect positioning of a single prosthetic heart valve into the proper anatomical location - Freedom from surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication - Intended performance of the valve (i.e., no moderate or severe prosthetic valve regurgitation)

    Time frame: 30 days

  2. Primary Safety Endpoint: VARC-3 Early Safety Composite

    Consisting of: - Freedom from all-cause mortality - Freedom from all stroke - Freedom from VARC type 2-4 bleeding - Freedom from major vascular, access-related, or cardiac structural complication - Freedom from acute kidney injury stage 3 or 4 - Freedom from moderate or severe aortic regurgitation - Freedom from new permanent pacemaker due to procedure related conduction abnormalities - Freedom from surgery or intervention related to the device\* Consisting of: - Freedom from all-cause mortality - Freedom from all stroke - Freedom from VARC type 2-4 bleeding - Freedom from major vascular, access-related, or cardiac structural complication - Freedom from acute kidney injury stage 3 or 4 - Freedom from moderate or severe aortic regurgitation - Freedom from new permanent pacemaker due to procedure related conduction abnormalities - Freedom from surgery or intervention related to the device\*

    Time frame: 30 days

Secondary outcomes

  1. Technical Success

    Technical Success According to VARC-3 Definition

    Time frame: At Exit From Procedure Room

  2. Device Performance

    Intended performance of the valve (i.e., no moderate or severe prosthetic valve regurgitation)\*

    Time frame: 30 days and 1 year

  3. Surgery/intervention related to device

    Freedom from surgery or intervention related to the device# or to a major vascular or access-related or cardiac structural complication

    Time frame: 30 days and 1 year

  4. Bleeding

    Freedom from VARC type 2-4 bleeding

    Time frame: 30 days and 1 year

  5. All Stroke

    Number of patients that had stroke

    Time frame: 30 days and 1 year

  6. Acute Kidney Injury

    Number of patients that had acute kidney injury (AKI) stage 3 or 4

    Time frame: 7 days

  7. Total aortic regurgitation

    Number of patients that had moderate or severe total aortic regurgitation

    Time frame: 30 days and 1 year

  8. Major Vascular Complication

    Number of patients that had major vascular, access-related, or cardiac structural complication

    Time frame: 30 days and 1 year

  9. Permanent pacemaker implantation

    Number of patients that had these events

    Time frame: 30 days

  10. All-cause mortality

    All-cause mortality

    Time frame: 30 days and 1 year

07

Study locations

14 sites
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2026, 20 months.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2024
First posted
Sep 19, 2024
StartActual
Dec 9, 2024
Primary completionActual
Aug 9, 2026
CompletionEst.
Aug 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Aug 9, 2026 (actual)
moved 2 times, Oct 26, 2026 – Oct 29, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 26, 2026
  • AddedPrimary Efficacy Endpoint: Modified VARC-3 Device SuccessTime frame: 30 days
  • AddedPrimary Safety Endpoint: VARC-3 Early Safety CompositeTime frame: 30 days
  • RemovedDevice SuccessTime frame: 30 days
  • RemovedDevice PositioningTime frame: 30 days
  • RemovedDevice PerformanceTime frame: 30 days
  • RemovedSurgery/intervention related to deviceTime frame: 30 days
  • RemovedBleedingTime frame: 30 days
  • RemovedAll StrokeTime frame: 30 days
  • RemovedAcute Kidney InjuryTime frame: 30 days
  • RemovedTotal aortic regurgitationTime frame: 30 days
  • RemovedMajor Vascular ComplicationTime frame: 30 days
  • RemovedPermanent pacemaker implantationTime frame: 30 days
  • RemovedAll-cause mortalityTime frame: 30 days
What changed on Oct 29, 2026
  • DescriptionPrimary Efficacy Endpoint: Modified VARC-3 Device Success: how it is measured was reworded
  • DescriptionPrimary Safety Endpoint: VARC-3 Early Safety Composite: how it is measured was reworded
across 2 updates, Oct 26, 2026 – Oct 29, 2026
Secondary outcomes
1 edited, 2 time frame changed, 1 removed, 1 description edited
What changed in the outcomes
  • EditedDeviceTechnical SuccessTime frame: 30 days and 1 year → At Exit From Procedure Room
  • RemovedDevice PositioningTime frame: 30 days and 1 year
  • Time frameAcute Kidney Injury30 days and 1 year → 7 days
  • Time framePermanent pacemaker implantation30 days and 1 year → 30 days
  • DescriptionAll-cause mortality: how it is measured was reworded
Oct 26, 2026
Show all 2 updates
  1. Oct 29, 2026
    Primary completion Aug 2027→Aug 9, 2026 (now actual)
    Primary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionPrimary Efficacy Endpoint: Modified VARC-3 Device Success: how it is measured was reworded
    • DescriptionPrimary Safety Endpoint: VARC-3 Early Safety Composite: how it is measured was reworded
  2. Oct 26, 2026
    Primary completion Aug 2026→Aug 2027
    Primary outcomes 2 added, 11 removed
    What changed in the outcomes
    • AddedPrimary Efficacy Endpoint: Modified VARC-3 Device SuccessTime frame: 30 days
    • AddedPrimary Safety Endpoint: VARC-3 Early Safety CompositeTime frame: 30 days
    • RemovedDevice SuccessTime frame: 30 days
    • RemovedDevice PositioningTime frame: 30 days
    • RemovedDevice PerformanceTime frame: 30 days
    • RemovedSurgery/intervention related to deviceTime frame: 30 days
    • RemovedBleedingTime frame: 30 days
    • RemovedAll StrokeTime frame: 30 days
    • RemovedAcute Kidney InjuryTime frame: 30 days
    • RemovedTotal aortic regurgitationTime frame: 30 days
    • RemovedMajor Vascular ComplicationTime frame: 30 days
    • RemovedPermanent pacemaker implantationTime frame: 30 days
    • RemovedAll-cause mortalityTime frame: 30 days
    Secondary outcomes 1 edited, 2 time frame changed, 1 removed, 1 description edited
    What changed in the outcomes
    • EditedDeviceTechnical SuccessTime frame: 30 days and 1 year → At Exit From Procedure Room
    • RemovedDevice PositioningTime frame: 30 days and 1 year
    • Time frameAcute Kidney Injury30 days and 1 year → 7 days
    • Time framePermanent pacemaker implantation30 days and 1 year → 30 days
    • DescriptionAll-cause mortality: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06594705
Lead sponsor
JenaValve Technology, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 9, 2024
Primary completion
Aug 9, 2026
Completion
Aug 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Nir Uriel, MD
study chair · Columbia University
Vinod Thourani, MD
principal investigator · Piedmont Heart Institute
Ravi Ramana, DO
principal investigator · advocate christ medical center
Gabriel Sayer, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion